Which weight loss injection has the most successful track record?

The misconception: "most successful" means one injection wins for everyone

It's a natural assumption. You look at the trial figures, pick the biggest number, and assume that medicine is the one. In practice, weight loss medicine doesn't work quite like that. The phrase "most successful weight loss injection" usually leads people to tirzepatide, and the clinical data does support that instinct at the population level, the evidence for tirzepatide's effectiveness puts it ahead of semaglutide in head-to-head comparisons. But population averages don't predict individual outcomes. Some people lose considerably more than the trial mean; others less. Some find semaglutide easier to tolerate. Some have a health history that shapes which medicine a prescriber is comfortable recommending.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomised 751 adults with obesity and no diabetes to either tirzepatide or semaglutide 2.4mg and followed them for 72 weeks. Tirzepatide produced greater average weight reduction. That is the strongest direct comparison we have. But the trial also shows that both medicines produced clinically meaningful weight loss, and that the gap between them narrowed with the newer 7.2mg semaglutide dose now approved in the UK. Success, in a clinical sense, means meaningful, sustained weight reduction that improves health, and both medicines can achieve that.

There is also the question of what "successful" means to you personally. For some people, losing 10% of body weight resolves sleep apnoea or brings blood pressure into a normal range. That counts as success even if the headline trial figure is higher.

What tirzepatide's trial numbers actually represent

Tirzepatide is a dual GIP and GLP-1 receptor agonist made by Eli Lilly, sold in the UK as Mounjaro. It is the only medicine in its class licensed here for weight management. In the SURMOUNT-1 trial, participants taking the 15mg dose achieved an average body-weight reduction of around 20–21% over 72 weeks. SURMOUNT-1 randomised 2,539 adults, which gives the findings real statistical weight. Understanding what those success rates mean in practice is worth doing before you draw conclusions from any single number.

The NHS patient information for tirzepatide explains that treatment starts at 2.5mg (a dose sized for tolerability, giving your body time to adjust) and is titrated upward over several months by the prescriber, not by the patient. NICE recommends tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related health condition, with lower thresholds applying for some ethnic backgrounds under UK guidance. How the safety profile compares to other options is a separate question, and an important one.

As with any prescription medicine, the dose that produces the best outcomes in a trial isn't necessarily the dose you'll reach, tolerability and clinical judgement shape that journey. Prescribers review progress and adjust accordingly. That ongoing relationship is part of what makes supervised treatment different from simply buying the medicine.

Where semaglutide fits, and why it remains widely used

Semaglutide (Wegovy) is a GLP-1 receptor agonist made by Novo Nordisk. The STEP 1 trial, also published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. That is a meaningful result on its own terms. The MHRA approved a higher 7.2mg semaglutide dose in early 2026, trial data for that dose reported around 20.7% average weight loss over 72 weeks, closing much of the gap with tirzepatide's top figures.

Semaglutide has a longer track record in UK clinical practice, and many prescribers and patients are very familiar with its tolerability profile. NICE recommends it under specific conditions (TA875), and it remains the injectable option available through NHS specialist services for those who qualify. The most commonly used weight loss injections and why they're prescribed are worth understanding before committing to one.

If needles are a barrier, it's also worth knowing that as of June 2026 the MHRA approved oral semaglutide (Wegovy tablets) for weight management, the first oral GLP-1 medicine licensed for this purpose in the UK. Comparing the injection and tablet routes may be relevant if you're deciding what form of treatment suits your routine.

What actually determines success day to day

Clinical trials measure averages. Real life adds variables: whether you can keep a consistent injection schedule, how you manage the early GI side effects that most people notice when starting or after a dose increase, whether your diet and activity habits shift alongside treatment. The NHS medicines page for tirzepatide lists the common side effects (nausea, loose stools, reflux and fatigue are the ones people mention most) and explains they typically settle within a couple of weeks of each dose step.

Timing matters too. A Monday order placed before 12pm arrives Tuesday; ordering just before a bank holiday or going away for a fortnight means thinking ahead so treatment stays consistent. Small logistical things, handled in advance, genuinely affect outcomes.

Access to aftercare also matters. A prescriber who reviews your progress before each repeat order, and a clinical team you can reach when a side effect worries you, makes a measurable difference to how long people stay on treatment and how much weight they ultimately lose. A broader look at weight loss injections covers the landscape if you're still at the research stage.

If you'd like to discuss which option fits your health picture, check your eligibility with our prescribers, the consultation is free, clinical, and reviewed the same day by a GPhC-registered prescriber.